

Torsten Witte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9350827/publications.pdf>

Version: 2024-02-01

99
papers

3,246
citations

185998

28
h-index

168136

53
g-index

110
all docs

110
docs citations

110
times ranked

5959
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
2	Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 124-131.	0.5	16
3	Diagnostic Yield and Therapeutic Consequences of Targeted Next-Generation Sequencing in Sporadic Primary Immunodeficiency. <i>International Archives of Allergy and Immunology</i> , 2022, 183, 337-349.	0.9	6
4	Common Variable Immunodeficiency-Associated Cancers: The Role of Clinical Phenotypes, Immunological and Genetic Factors. <i>Frontiers in Immunology</i> , 2022, 13, 742530.	2.2	14
5	Natural antibodies and CRP drive anaphylatoxin production by urate crystals. <i>Scientific Reports</i> , 2022, 12, 4483.	1.6	2
6	Kappa Free Light Chains in Cerebrospinal Fluid in Inflammatory and Non-Inflammatory Neurological Diseases. <i>Brain Sciences</i> , 2022, 12, 475.	1.1	9
7	Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis. <i>Biomedicines</i> , 2022, 10, 1629.	1.4	3
8	Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. <i>Rheumatology</i> , 2021, 60, 113-124.	0.9	3
9	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	2.9	81
10	Use of Complementary and Alternative Medicine in Patients with Primary Immunodeficiency: a Multicentric Analysis of 101 Patients. <i>Journal of Clinical Immunology</i> , 2021, 41, 585-594.	2.0	2
11	A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry. <i>Journal of Medical Internet Research</i> , 2021, 23, e28164.	2.1	13
12	CIDP associated with Sjögren's syndrome. <i>Journal of Neurology</i> , 2021, 268, 2908-2912.	1.8	15
13	Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1122-1140.	4.8	43
14	Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs. <i>Diagnostics</i> , 2021, 11, 1132.	1.3	2
15	B cell depletion impairs vaccination-induced CD8 ⁺ T cell responses in a type I interferon-dependent manner. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1537-1544.	0.5	20
16	Nerve ultrasound findings in Sjögren's syndrome-associated neuropathy. <i>Journal of Neuroimaging</i> , 2021, 31, 1156-1165.	1.0	5
17	Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study. <i>Rheumatology</i> , 2021, 60, 4085-4093.	0.9	8
18	The Influence of Renal Function Impairment on Kappa Free Light Chains in Cerebrospinal Fluid. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110421.	0.7	10

#	ARTICLE	IF	CITATIONS
19	Vulnerability to Meningococcal Disease in Immunodeficiency Due to a Novel Pathogenic Missense Variant in NFKB1. <i>Frontiers in Immunology</i> , 2021, 12, 767188.	2.2	2
20	Multimodal Assessment and Characterization of Sicca Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 777599.	1.2	8
21	Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV. <i>PLoS Pathogens</i> , 2020, 16, e1008560.	2.1	16
22	Cognitive impairment in patients with Neuro-Sjögren. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1352-1359.	1.7	14
23	Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. <i>Infectious Diseases and Therapy</i> , 2020, 9, 837-849.	1.8	34
24	Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 4067.	1.0	53
25	Hearing dysfunction in patients with Neuro-Sjögren: a cross-sectional study. <i>Annals of Translational Medicine</i> , 2020, 8, 1069-1069.	0.7	9
26	Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 1482.	1.0	13
27	Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS. <i>Frontiers in Immunology</i> , 2020, 11, 1059.	2.2	20
28	Presence of Antibodies Binding to Negative Elongation Factor E in Sarcoidosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 715.	1.0	3
29	Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. <i>Infection</i> , 2020, 48, 631-634.	2.3	69
30	C-reactive protein (CRP) recognizes uric acid crystals and recruits proteases C1 and MASP1. <i>Scientific Reports</i> , 2020, 10, 6391.	1.6	19
31	The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. <i>Cells</i> , 2020, 9, 842.	1.8	25
32	Peripheral Blood Lymphocyte Phenotype Differentiates Secondary Antibody Deficiency in Rheumatic Disease from Primary Antibody Deficiency. <i>Journal of Clinical Medicine</i> , 2020, 9, 1049.	1.0	9
33	IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1127-1131.	0.4	5
34	Title is missing!. , 2020, 16, e1008560.		0
35	Title is missing!. , 2020, 16, e1008560.		0
36	Title is missing!. , 2020, 16, e1008560.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 16, e1008560.		0
38	Title is missing!. , 2020, 16, e1008560.		0
39	Title is missing!. , 2020, 16, e1008560.		0
40	Title is missing!. , 2020, 16, e1008560.		0
41	Title is missing!. , 2020, 16, e1008560.		0
42	Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 1600.	2.2	64
43	Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence. <i>Frontiers in Immunology</i> , 2019, 10, 574.	2.2	22
44	048.â€fINCREASED SENSITIVITY FOR PR3-ANCA USING A NOVEL CHEMILUMINESCENCE IMMUNOASSAY. <i>Rheumatology</i> , 2019, 58, .	0.9	0
45	HLAâ€B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 708-714.	0.9	15
46	AB0698â€fEFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY. , 2019, , .		0
47	Reiberâ€™s Diagram for Kappa Free Light Chains: The New Standard for Assessing Intrathecal Synthesis?. <i>Diagnostics</i> , 2019, 9, 194.	1.3	24
48	Sensitivity and Specificity of Autoantibodies Against CD 74 in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 729-735.	2.9	31
49	Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. <i>Rheumatology</i> , 2018, 57, 1309-1310.	0.9	13
50	Autoimmunity and primary immunodeficiency: two sides of the same coin?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 7-18.	3.5	103
51	Histamine H2 receptor stimulation upregulates T H 2 chemokine CCL17 production in human M2a macrophages. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 782-785.e5.	1.5	8
52	Preliminary Study on Antinuclear Antibodies in Patients With Chronic Dilatory Eustachian Tube Dysfunction. <i>Otology and Neurotology</i> , 2018, 39, e612-e617.	0.7	1
53	188â€fReal-world data on the use of certolizumab pegol for the treatment of axial spondyloarthritis in clinical practice in Europe: 24-week interim results from a prospective non-interventional cohort study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
54	Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More?. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 170.	1.1	3

#	ARTICLE	IF	CITATIONS
55	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	1.1	3
56	The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3796.	1.8	34
57	Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2018, 8, 8195.	1.6	17
58	Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 38.	1.6	35
59	Evaluation of RAG1 mutations in an adult with combined immunodeficiency and progressive multifocal leukoencephalopathy. <i>Clinical Immunology</i> , 2017, 179, 1-7.	1.4	24
60	Limited role of interferon-kappa (IFNK) truncating mutations in common variable immunodeficiency. <i>Cytokine</i> , 2017, 96, 71-74.	1.4	2
61	Cerebrospinal Fluid Findings in Neurological Diseases Associated with Sjögren's Syndrome. <i>European Neurology</i> , 2017, 77, 91-102.	0.6	27
62	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
63	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2187-2192.	2.9	35
64	Comment on: New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e11.	1.6	0
65	LILRA3 deletion is a genetic risk factor of HIV infection. <i>Aids</i> , 2017, 31, 25-34.	1.0	6
66	Autoantibodies binding to stathmin-4: new marker for polyneuropathy in primary Sjögren's syndrome. <i>Immunologic Research</i> , 2017, 65, 1099-1102.	1.3	8
67	Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?. <i>Frontiers in Immunology</i> , 2017, 8, 1595.	2.2	5
68	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820.	1.5	60
69	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	2.9	114
70	CD4+ T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 586-589.e10.	1.5	23
71	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29.	1.4	68
72	TLR8 regulation of LILRA3 in monocytes is abrogated in human immunodeficiency virus infection and correlates to CD4 counts and virus loads. <i>Retrovirology</i> , 2016, 13, 15.	0.9	10

#	ARTICLE	IF	CITATIONS
73	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	2.9	46
74	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.5	41
75	LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 208-209.	0.4	0
76	Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64+ cells. <i>Scientific Reports</i> , 2015, 5, 18308.	1.6	4
77	IgG4-related sialadenitis: IgG4 is helpful, but biopsies are still crucial. <i>Arthritis Research and Therapy</i> , 2015, 17, 368.	1.6	4
78	PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e14-e14.	0.5	24
79	Analysis of Specific IgG Titers Against Tick-Borne Encephalitis in Patients with Primary Antibody Deficiency Under Immunoglobulin Substitution Therapy: Impact of Plasma Donor Origin. <i>Frontiers in Immunology</i> , 2015, 5, 675.	2.2	6
80	Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?. <i>Clinical Rheumatology</i> , 2015, 34, 629-634.	1.0	22
81	Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells. <i>Nature Communications</i> , 2015, 6, 6804.	5.8	63
82	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
83	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596.	1.4	74
84	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.4	4
85	Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis. <i>PLoS ONE</i> , 2014, 9, e85330.	1.1	61
86	Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. <i>Nature Medicine</i> , 2014, 20, 1410-1416.	15.2	723
87	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
88	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	1.1	17
89	Association of the LILRA3 Deletion with B-NHL and Functional Characterization of the Immunostimulatory Molecule. <i>PLoS ONE</i> , 2013, 8, e81360.	1.1	11
90	Leukocyte Immunoglobulin-Like Receptors as New Players in Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 159-162.	2.9	28

#	ARTICLE	IF	CITATIONS
91	Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. <i>Rheumatology</i> , 2009, 48, 796-799.	0.9	66
92	Higher risk of cytomegalovirus reactivation in human immunodeficiency virus-infected patients homozygous for MICA5.1. <i>Human Immunology</i> , 2009, 70, 175-178.	1.2	16
93	Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 994-1003.	0.6	13
94	IgM Antibodies Against dsDNA in SLE. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 345-347.	2.9	65
95	Antibodies against Alpha-Fodrin Are Associated with Sicca Syndrome in the General Population. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 414-417.	1.8	15
96	Antifodrin Antibodies in Sjögren's Syndrome: A Review. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 235-239.	1.8	30
97	Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB × NZW) F1 hybrid strain. <i>Journal of Autoimmunity</i> , 1995, 8, 107-114.	6.7	95
98	Antibodies against alpha-fodrin in Sjögren's syndrome. <i>Autoimmunity Reviews</i> , 2003, 2, 109-113.	2.5	34
99	Prevalence of antibodies against alpha-fodrin in Sjögren's syndrome: comparison of 2 sets of classification criteria. <i>Journal of Rheumatology</i> , 2003, 30, 2157-9.	1.0	27